The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

The G7 15 Day CGM in use. [Image courtesy of Dexcom] Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month. The San ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Trio does not backfill missed glucose readings when connected via the Dexcom G7 connector. This results in gaps in BG history for the Trio app, even though the Dexcom G7 app successfully backfills ...

Thousands of engineering professionals are expected June 6-7 at the Donald E. Stephens Convention Center in Rosemont, IL for the 2012 Sensors Expo & Conference. June 2, 2012 - Thousands of engineering ...

50 sessions will be offered June 6-7, 2012, in nine tracks: MEMS, Energy Harvesting, Wireless Sensing Solutions, Sensor and System Design, Novel Approaches to Measurement & Detection, Big Data & ...